23:44 , Aug 6, 2019 |  BC Extra  |  Company News

Aug. 6 Company Quick Takes: Sales updates from Alnylam, Sage, Regeneron and GW; plus regulatory updates from MorphoSys and more

Alnylam's Onpattro bests consensus  Sales of amyloidosis therapy Onpattro patisiran from Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) reached $38.2 million in 2Q19, the drug's third full quarter on the market. The figure beat analysts' consensus of $32...
00:30 , Jul 27, 2019 |  BioCentury  |  Product Development

How Gilead deal positions Galapagos to become Europe’s next big biotech

Galapagos’ pipeline partnership with Gilead sets the company up to become an independent leader of European biotech for years to come, and provides a template that other platform companies could follow. The July 14 deal...
22:59 , Jul 8, 2019 |  BC Extra  |  Company News

July 8 Company Quick Takes: Merck, Skyhawk in discovery deal; plus MorphoSys, BioMarin, Roche-Spark and Hanmi

Skyhawk, Merck in neurology, cancer deal  Skyhawk Therapeutics Inc. (Waltham, Mass.) and Merck & Co. Inc. (NYSE:MRK) parterned to discover, develop and commercialize small molecules capable of modulating RNA splicing discovered using Skyhawk’s SkySTAR platform...
21:23 , Jul 3, 2019 |  BC Extra  |  Clinical News

July 3 Clinical Quick Takes: GSK starts Phase III otilimab RA program; plus Unum, Xofluza and more

Otilimab triggers milestone for MorphoSys MorphoSys AG (Xetra:MOR; NASDAQ:MOR) will receive a milestone payment of €22 million ($27.7 million) after partner GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) started the Phase III ContRAst program of otilimab to treat...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:32 , Jun 24, 2019 |  BC Extra  |  Company News

Management Tracks: Kress to succeed Moroney at MorphoSys; plus Sutro, Entasis and more

MorphoSys AG (Xetra:MOR; NASDAQ:MOR) said Jean-Paul Kress will take over as CEO from Simon Moroney, who in February announced his decision not to renew his contract as a member of MorphoSys’ management board, on Sept....
23:50 , Jun 14, 2019 |  BC Extra  |  Clinical News

June 14 Clinical Quick Takes: Chi-Med, BeiGene, UCB, Global Blood and more

Chi-Med’s surufatinib meets in Phase III for extra-pancreatic neuroendocrine tumors  Hutchison China MediTech Ltd. (LSE:HCM; NASDAQ:HCM) said it is planning a pre-NDA meeting with China’s National Medical Products Administration (NMPA) after surufatinib (formerly sulfatinib) met...
18:42 , Jun 3, 2019 |  BioCentury  |  Product Development

There are opportunities to eradicate opioid misuse: Investors and innovators should seize them

Eradicating opioid misuse and addiction will take an integrated, holistic approach involving prevention, treatment, and recovery. Crucially, it will also take the help of investors and innovators in biotechnology who understand the challenges and opportunities...
20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
23:21 , May 23, 2019 |  BC Extra  |  Company News

With Merck veterans at the helm, Nektar launches subsidiary for pain compound

Nektar has been signaling for months that it planned to create a subsidiary to house analgesic NKTR-181, with a financial partner on board to fuel a commercial launch. Now that it has launched Inheris, the...